Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey
Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outc...
Saved in:
| Published in | Lower urinary tract symptoms Vol. 5; no. 1; pp. 5 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.01.2013
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1757-5664 1757-5672 1757-5672 |
| DOI | 10.1111/j.1757-5672.2012.00155.x |
Cover
| Abstract | Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36‐Item Short Form Health Survey (SF‐36).
Methods: We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease‐specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health‐related QoL (HRQoL) were assessed using the OABSS and SF‐36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated.
Results: Seventy‐eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF‐36 domains were significantly worse than the age‐ and gender‐adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra‐group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF‐36 scales (physical function [PF], VT, and MH) significantly improved after treatment.
Conclusion: Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease‐specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF‐36, solifenacin treatment effectively improves three SF‐36 scores: PF, VT, and MH. |
|---|---|
| AbstractList | Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36‐Item Short Form Health Survey (SF‐36).
Methods: We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease‐specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health‐related QoL (HRQoL) were assessed using the OABSS and SF‐36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated.
Results: Seventy‐eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF‐36 domains were significantly worse than the age‐ and gender‐adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra‐group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF‐36 scales (physical function [PF], VT, and MH) significantly improved after treatment.
Conclusion: Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease‐specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF‐36, solifenacin treatment effectively improves three SF‐36 scores: PF, VT, and MH. Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Methods: We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease-specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health-related QoL (HRQoL) were assessed using the OABSS and SF-36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated. Results: Seventy-eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF-36 domains were significantly worse than the age- and gender-adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra-group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF-36 scales (physical function [PF], VT, and MH) significantly improved after treatment. Conclusion: Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease-specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF-36, solifenacin treatment effectively improves three SF-36 scores: PF, VT, and MH. [PUBLICATION ABSTRACT] We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease-specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health-related QoL (HRQoL) were assessed using the OABSS and SF-36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated. Seventy-eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF-36 domains were significantly worse than the age- and gender-adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra-group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF-36 scales (physical function [PF], VT, and MH) significantly improved after treatment. Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease-specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF-36, solifenacin treatment effectively improves three SF-36 scores: PF, VT, and MH. Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36‐Item Short Form Health Survey (SF‐36). Methods: We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease‐specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health‐related QoL (HRQoL) were assessed using the OABSS and SF‐36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated. Results: Seventy‐eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF‐36 domains were significantly worse than the age‐ and gender‐adjusted Japanese national norms ( P < 0.01), except the vitality (VT) scale. Intra‐group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF‐36 scales (physical function [PF], VT, and MH) significantly improved after treatment. Conclusion: Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease‐specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF‐36, solifenacin treatment effectively improves three SF‐36 scores: PF, VT, and MH. We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).OBJECTIVESWe evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed overactive bladder (OAB) by prospectively analyzing improvements in the overactive bladder symptom score (OABSS) and the Rand Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).We prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease-specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health-related QoL (HRQoL) were assessed using the OABSS and SF-36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated.METHODSWe prospectively recruited newly diagnosed female patients with OAB. Pretreatment disease-specific symptoms were documented, and generic QoL questionnaires were administered. All subjects received solifenacin 5 mg/day for >8 weeks. Symptoms and general health-related QoL (HRQoL) were assessed using the OABSS and SF-36, respectively. Other objective variables, such as maximum urinary flow rate and postvoid residual urine volume, were also evaluated.Seventy-eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF-36 domains were significantly worse than the age- and gender-adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra-group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF-36 scales (physical function [PF], VT, and MH) significantly improved after treatment.RESULTSSeventy-eight subjects met all inclusion criteria and no exclusion criteria. After 8 weeks, the mean OABSS decreased by approximately 50% compared with baseline (from 9.1 ± 2.8 to 4.5 ± 3.6). All individual scores in OABSS improved after administration of solifenacin. Before treatment, the scores of the study subjects in all SF-36 domains were significantly worse than the age- and gender-adjusted Japanese national norms (P < 0.01), except the vitality (VT) scale. Intra-group comparisons between age groups showed worse mental health (MH) scores in all age groups. In the OAB group, three mean SF-36 scales (physical function [PF], VT, and MH) significantly improved after treatment.Treatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease-specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF-36, solifenacin treatment effectively improves three SF-36 scores: PF, VT, and MH.CONCLUSIONTreatment of OAB with solifenacin is associated with significant improvement in generic HRQoL and disease-specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the SF-36, solifenacin treatment effectively improves three SF-36 scores: PF, VT, and MH. |
| Author | NOMURA, Kazushi MIKAMI, Kazuo YANO, Masashi KATO, Tomonori OHTA, Sho NAKATSU, Hiroomi ICHIKAWA, Tomohiko SUZUKI, Hiroyoshi ONISHI, Tetsuro OKANO, Tatsuya KURAMOCHI, Hiroaki KAMIYA, Naoto |
| Author_xml | – sequence: 1 givenname: Masashi surname: YANO fullname: YANO, Masashi organization: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, Japan – sequence: 2 givenname: Hiroyoshi surname: SUZUKI fullname: SUZUKI, Hiroyoshi email: hiroyoshi.suzuki@med.toho-u.ac.jp organization: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, Japan – sequence: 3 givenname: Naoto surname: KAMIYA fullname: KAMIYA, Naoto organization: Department of Urology, Toho University Sakura Medical Center, Sakura-shi, Japan – sequence: 4 givenname: Tomonori surname: KATO fullname: KATO, Tomonori organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 5 givenname: Kazushi surname: NOMURA fullname: NOMURA, Kazushi organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 6 givenname: Hiroaki surname: KURAMOCHI fullname: KURAMOCHI, Hiroaki organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 7 givenname: Sho surname: OHTA fullname: OHTA, Sho organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 8 givenname: Kazuo surname: MIKAMI fullname: MIKAMI, Kazuo organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 9 givenname: Hiroomi surname: NAKATSU fullname: NAKATSU, Hiroomi organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 10 givenname: Tatsuya surname: OKANO fullname: OKANO, Tatsuya organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 11 givenname: Tetsuro surname: ONISHI fullname: ONISHI, Tetsuro organization: Chiba Continence Research Society, Chiba-shi, Japan – sequence: 12 givenname: Tomohiko surname: ICHIKAWA fullname: ICHIKAWA, Tomohiko organization: Chiba Continence Research Society, Chiba-shi, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26663241$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkc2O0zAUhSM0iPmBV0CW2LBJsRPHSZBYQMV0KpWpmEzF0nKdG8bFsYOTtM178kA47UwXiAV4YVv2-e499rkMzow1EASI4Anx491mQtIkDROWRpMIk2iCMUmSyf5ZcHG6ODvtGT0PLtt2gzFLCU1eBOcRYyyOKLkIfk21MkoKjeZ1I2SHbIUKq1UFRkhlkDVoBgackkiYEhVD3XS2DosGpKr84ddeaNUNI7bwEKqsQ9dQCw0t2qnuAS234HxdtQX0SYuyBPcerVplvqPuAf5y-9QCFdI6ODS9G6cvUB5sLvtO2tpXL7q-HFDMwnkHNboBoX23ondbGF4GzyuhW3j1uF4Fq-vP99ObcLGczacfF6GkMU5CyHFJsqj0PyTLcp1Iuk5Tuk4oSzDOE5bTKo-kxIRkIl8DLlMcpyQDSDGtsgTHV0F-rNubRgw7oTVvnKqFGzjBfEyKb_gYAh8D4WNS_JAU33v27ZFtnP3ZQ9vxWrUStBYGbN96jOZ5zjCJvfTNH9KN7Z3xL-Mkpox4t3Q08_pR1a9rKE9OnrL2guwokM62rYPqf8x-OKI7pWH4Z44vVveF33k-PPKq7WB_4oX7wVkapwn_djvjt-kix9l0xu_i32144Ac |
| Cites_doi | 10.1111/j.1442-2042.2006.01594.x 10.1016/j.lfs.2003.07.019 10.4065/78.6.687 10.1016/S0895-4356(98)00095-X 10.1016/S0090-4295(97)00602-X 10.1016/S0002-9343(96)00174-X 10.1016/j.eururo.2004.11.004 10.1046/j.1464-410x.1999.00004.x 10.1097/00005650-199206000-00002 10.1097/01.ju.0000127742.73136.0c 10.1007/BF00451721 10.1034/j.1600-0412.2001.801117.x 10.1046/j.1464-410X.2002.02963.x 10.1111/j.1471-0528.1997.tb11006.x 10.1007/s00210-002-0554-x 10.1111/j.1532-5415.1994.tb06537.x 10.1007/s101980100064 10.2165/00019053-199814050-00005 10.1111/j.1471-0528.2004.00129.x 10.1097/00005650-199401000-00004 10.1023/A:1016370925601 10.1016/S0090-4295(00)01113-4 |
| ContentType | Journal Article |
| Copyright | 2012 Blackwell Publishing Asia Pty Ltd 2012 Blackwell Publishing Asia Pty Ltd. Copyright 2012 Blackwell Publishing Asia Pty Ltd |
| Copyright_xml | – notice: 2012 Blackwell Publishing Asia Pty Ltd – notice: 2012 Blackwell Publishing Asia Pty Ltd. – notice: Copyright 2012 Blackwell Publishing Asia Pty Ltd |
| DBID | BSCLL AAYXX CITATION NPM K9. 7X8 ADTOC UNPAY |
| DOI | 10.1111/j.1757-5672.2012.00155.x |
| DatabaseName | Istex CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1757-5672 |
| EndPage | 10 |
| ExternalDocumentID | 10.1111/j.1757-5672.2012.00155.x 2954851011 26663241 10_1111_j_1757_5672_2012_00155_x LUTS155 ark_67375_WNG_N7L908CG_R |
| Genre | article Journal Article |
| GroupedDBID | --- 05W 0R~ 1OC 33P 3SF 4.4 50Y 52U 52V 53G 5DZ 8-1 AAESR AAEVG AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACMXC ACPOU ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADXAS ADZMN AEIGN AEIMD AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AGQPQ AGYGG AHBTC AHMBA AIACR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BRXPI BSCLL C45 CAG COF DCZOG DRFUL DRMAN DRSTM EBS EJD F5P FEDTE FUBAC G-S GODZA H.X HGLYW HVGLF HZ~ KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY. MY~ NF~ O66 O9- OIG OVD P2W PQQKQ Q.N QB0 ROL RX1 SUPJJ TEORI WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR XV2 ZZTAW AAYXX CITATION A00 AAHHS ACCFJ ACUHS AEEZP AEQDE AFPWT AIWBW AJBDE NPM P4E K9. 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c4305-e90d182d566cddb5c4b774b54650095694f92cc0118a9be0d703718ee704f8503 |
| IEDL.DBID | UNPAY |
| ISSN | 1757-5664 1757-5672 |
| IngestDate | Tue Aug 19 18:01:23 EDT 2025 Thu Jul 10 17:17:18 EDT 2025 Tue Oct 07 06:28:29 EDT 2025 Wed Feb 19 01:59:37 EST 2025 Wed Oct 01 05:09:58 EDT 2025 Sun Sep 21 06:22:17 EDT 2025 Sun Sep 21 06:20:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Rand Medical Outcomes Study 36-Item Short Form Health Survey antimuscarinic agent quality of life overactive bladder overactive bladder symptom score |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2012 Blackwell Publishing Asia Pty Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4305-e90d182d566cddb5c4b774b54650095694f92cc0118a9be0d703718ee704f8503 |
| Notes | ArticleID:LUTS155 istex:B9C4DEE125A5E8DED76FE3DFD744BD2EF7CAAAAD ark:/67375/WNG-N7L908CG-R ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1757-5672.2012.00155.x |
| PMID | 26663241 |
| PQID | 1346150040 |
| PQPubID | 1016396 |
| PageCount | 6 |
| ParticipantIDs | unpaywall_primary_10_1111_j_1757_5672_2012_00155_x proquest_miscellaneous_1749996013 proquest_journals_1346150040 pubmed_primary_26663241 crossref_primary_10_1111_j_1757_5672_2012_00155_x wiley_primary_10_1111_j_1757_5672_2012_00155_x_LUTS155 istex_primary_ark_67375_WNG_N7L908CG_R |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01 January 2013 2013-01-00 2013-Jan 20130101 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Australia – name: Fukushima |
| PublicationTitle | Lower urinary tract symptoms |
| PublicationTitleAlternate | Low Urin Tract Symptoms |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95. Hagglund D, Walker-Engstrom ML, Larsson G, Leppert J. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand 2001; 80: 1051-5. Suzuki H, Yano M, Awa Y et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for prostatic hyperplasia patients: using international prostate symptom score and Rand medical outcomes study 36-item health survey. Int J Urol 2006; 13: 1202-6. Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2t mobilization study in monkey cells. Life Sci 2004; 74: 843-53. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83. Haab F, Cardozo L, Chapple C et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998; 14: 531-9. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin. Epidemiol 1998; 51: 1037-44. Shumaker SA, Wyman JF, Uebersax JS et al. Health-ralated quality of life measures for women with incontinence: the incontinence impact questionnaire and the urological distress inventory. Continence program in women (CPW) research group. Qual Life Res 1994; 3: 291-306. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74. Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9. Kutner NG, Schechtman KB, Ory MG, Baker DI. Older adults' perceptions of their health and functioning in relation to sleep disturbance, falling, and urinary incontinence. FICSIT Group. J Am Geriatr Soc 1994; 42: 757-62. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50: S100-7. Chapple C, Ballanger P, Hatzichristou D et al. Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin vs. tolterodine multinational trial (STAR study). Neurourol Urodyn 2005; 24: 401-598, abstract 111. Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? BJOG 2004; 111: 605-12. Komaroff AL, Fagioli LR, Doolittle TH et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101: 281-90. Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103. Ko Y, Lin SJ, Salmon JW, Bron M. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11: S103-11. Van der Vaart CH, De Leeuw JRJ, Roovers JPWR, Heintz AP. The effects of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 2002; 90: 544-9. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583-90. Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Health Econ Prev Care 2001; 2: 69-75. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66. Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21. Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Man Care 2002; 8: S616-30. Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171(6 Pt 1): 2311-5. 2006; 13 2002; 8 2002; 11 1997 2003 1999; 83 1996; 101 2005; 24 1992; 30 1994; 42 2003; 78 2005; 47 2001; 80 2004; 111 2004; 74 1997; 104 1997; 50 2001 2002; 366 2004; 171 2001; 2 2002; 90 1998; 51 1994; 3 2001; 57 2005; 11 1994; 32 1998; 14 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_17_2 Chapple C (e_1_2_7_23_2) 2005; 24 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_11_2 e_1_2_7_10_2 Ko Y (e_1_2_7_18_2) 2005; 11 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_22_2 e_1_2_7_21_2 Kelleher CJ (e_1_2_7_12_2) 2002; 8 e_1_2_7_20_2 |
| References_xml | – reference: Shumaker SA, Wyman JF, Uebersax JS et al. Health-ralated quality of life measures for women with incontinence: the incontinence impact questionnaire and the urological distress inventory. Continence program in women (CPW) research group. Qual Life Res 1994; 3: 291-306. – reference: Van der Vaart CH, De Leeuw JRJ, Roovers JPWR, Heintz AP. The effects of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 2002; 90: 544-9. – reference: O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998; 14: 531-9. – reference: Komaroff AL, Fagioli LR, Doolittle TH et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101: 281-90. – reference: Chapple C, Ballanger P, Hatzichristou D et al. Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin vs. tolterodine multinational trial (STAR study). Neurourol Urodyn 2005; 24: 401-598, abstract 111. – reference: Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2t mobilization study in monkey cells. Life Sci 2004; 74: 843-53. – reference: Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? BJOG 2004; 111: 605-12. – reference: Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171(6 Pt 1): 2311-5. – reference: Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583-90. – reference: Suzuki H, Yano M, Awa Y et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for prostatic hyperplasia patients: using international prostate symptom score and Rand medical outcomes study 36-item health survey. Int J Urol 2006; 13: 1202-6. – reference: Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83. – reference: Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74. – reference: Hagglund D, Walker-Engstrom ML, Larsson G, Leppert J. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand 2001; 80: 1051-5. – reference: Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95. – reference: Kutner NG, Schechtman KB, Ory MG, Baker DI. Older adults' perceptions of their health and functioning in relation to sleep disturbance, falling, and urinary incontinence. FICSIT Group. J Am Geriatr Soc 1994; 42: 757-62. – reference: McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66. – reference: Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9. – reference: Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Man Care 2002; 8: S616-30. – reference: Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Health Econ Prev Care 2001; 2: 69-75. – reference: Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin. Epidemiol 1998; 51: 1037-44. – reference: Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21. – reference: Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103. – reference: Ko Y, Lin SJ, Salmon JW, Bron M. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11: S103-11. – reference: Haab F, Cardozo L, Chapple C et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84. – reference: Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50: S100-7. – volume: 42 start-page: 757 year: 1994 end-page: 62. article-title: Older adults' perceptions of their health and functioning in relation to sleep disturbance, falling, and urinary incontinence. FICSIT Group. publication-title: J Am Geriatr Soc – volume: 366 start-page: 97 year: 2002 end-page: 103. article-title: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. publication-title: Naunyn Schmiedebergs Arch Pharmacol – volume: 78 start-page: 687 year: 2003 end-page: 95. article-title: Prospective, randomized, double‐blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. publication-title: Mayo Clin Proc – volume: 3 start-page: 291 year: 1994 end-page: 306. article-title: Health‐ralated quality of life measures for women with incontinence: the incontinence impact questionnaire and the urological distress inventory. Continence program in women (CPW) research group. publication-title: Qual Life Res – volume: 74 start-page: 843 year: 2004 end-page: 53. article-title: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2t mobilization study in monkey cells. publication-title: Life Sci – volume: 11 start-page: 563 year: 2002 end-page: 74. article-title: Psychometric validation of an overactive bladder symptom and health‐related quality of life questionnaire: the OAB‐q. publication-title: Qual Life Res – volume: 8 start-page: S616 year: 2002 end-page: 30. article-title: Long‐term health‐related quality of life of patients receiving extended release tolterodine for overactive bladder. publication-title: Am J Man Care – volume: 90 start-page: 544 year: 2002 end-page: 9. article-title: The effects of urinary incontinence and overactive bladder symptoms on quality of life in young women. publication-title: BJU Int – volume: 57 start-page: 414 year: 2001 end-page: 21. article-title: Tolterodine once‐daily: superior efficacy and tolerability in the treatment of the overactive bladder. publication-title: Urology – volume: 47 start-page: 376 year: 2005 end-page: 84. article-title: Long‐term open‐label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. publication-title: Eur Urol – volume: 32 start-page: 40 year: 1994 end-page: 66 article-title: The MOS 36‐item Short‐Form Health Survey (SF‐36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups publication-title: Med Care – volume: 24 start-page: 401 year: 2005 end-page: 598 article-title: Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin vs. tolterodine multinational trial (STAR study). publication-title: Neurourol Urodyn – volume: 51 start-page: 1037 year: 1998 end-page: 44. article-title: Translation, adaptation, and validation of the SF‐36 Health Survey for use in Japan. publication-title: J Clin. Epidemiol – start-page: 25 year: 2001 end-page: 27 – volume: 111 start-page: 605 year: 2004 end-page: 12. article-title: How much is enough and who says so? publication-title: BJOG – volume: 80 start-page: 1051 year: 2001 end-page: 5. article-title: Quality of life and seeking help in women with urinary incontinence. publication-title: Acta Obstet Gynecol Scand – volume: 14 start-page: 531 year: 1998 end-page: 9. article-title: Urge incontinence. Quality of life and patients' valuation of symptom reduction. publication-title: Pharmacoeconomics – volume: 101 start-page: 281 year: 1996 end-page: 90. article-title: Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. publication-title: Am J Med – volume: 50 start-page: S100 year: 1997 end-page: 7. article-title: Economic considerations and outcome measurement in urge incontinence. publication-title: Urology – volume: 104 start-page: 1374 year: 1997 end-page: 9. article-title: A new questionnaire to assess the quality of life of urinary incontinent women. publication-title: Br J Obstet Gynaecol – volume: 171 start-page: 2311 issue: 6 Pt 1 year: 2004 end-page: 5. article-title: Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. publication-title: J Urol – start-page: 23 year: 1997 end-page: 26 – volume: 2 start-page: 69 year: 2001 end-page: 75. article-title: Health‐related quality of life of patients with overactive bladder receiving immediate‐release tolterodine. publication-title: Health Econ Prev Care – volume: 11 start-page: S103 year: 2005 end-page: 11. article-title: The impact of urinary incontinence on quality of life of the elderly. publication-title: Am J Manag Care – start-page: 2 year: 2003 end-page: 7 – volume: 30 start-page: 473 year: 1992 end-page: 83. article-title: The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. publication-title: Med Care – volume: 83 start-page: 583 year: 1999 end-page: 90. article-title: Quality‐of‐life aspects of the overactive bladder and the effect of treatment with tolterodine publication-title: BJU Int – volume: 13 start-page: 1202 year: 2006 end-page: 6. article-title: Clinical impact of tamsulosin on generic and symptom‐specific quality of life for prostatic hyperplasia patients: using international prostate symptom score and Rand medical outcomes study 36‐item health survey. publication-title: Int J Urol – ident: e_1_2_7_9_2 doi: 10.1111/j.1442-2042.2006.01594.x – ident: e_1_2_7_6_2 doi: 10.1016/j.lfs.2003.07.019 – ident: e_1_2_7_25_2 doi: 10.4065/78.6.687 – ident: e_1_2_7_10_2 doi: 10.1016/S0895-4356(98)00095-X – ident: e_1_2_7_20_2 doi: 10.1016/S0090-4295(97)00602-X – ident: e_1_2_7_5_2 doi: 10.1016/S0002-9343(96)00174-X – ident: e_1_2_7_29_2 doi: 10.1016/j.eururo.2004.11.004 – ident: e_1_2_7_2_2 doi: 10.1046/j.1464-410x.1999.00004.x – ident: e_1_2_7_8_2 doi: 10.1097/00005650-199206000-00002 – ident: e_1_2_7_26_2 doi: 10.1097/01.ju.0000127742.73136.0c – ident: e_1_2_7_16_2 doi: 10.1007/BF00451721 – ident: e_1_2_7_19_2 doi: 10.1034/j.1600-0412.2001.801117.x – ident: e_1_2_7_17_2 doi: 10.1046/j.1464-410X.2002.02963.x – ident: e_1_2_7_14_2 doi: 10.1111/j.1471-0528.1997.tb11006.x – ident: e_1_2_7_7_2 doi: 10.1007/s00210-002-0554-x – ident: e_1_2_7_22_2 doi: 10.1111/j.1532-5415.1994.tb06537.x – ident: e_1_2_7_13_2 doi: 10.1007/s101980100064 – ident: e_1_2_7_3_2 – ident: e_1_2_7_21_2 doi: 10.2165/00019053-199814050-00005 – volume: 24 start-page: 401 year: 2005 ident: e_1_2_7_23_2 article-title: Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin vs. tolterodine multinational trial (STAR study). publication-title: Neurourol Urodyn – ident: e_1_2_7_27_2 doi: 10.1111/j.1471-0528.2004.00129.x – volume: 11 start-page: S103 year: 2005 ident: e_1_2_7_18_2 article-title: The impact of urinary incontinence on quality of life of the elderly. publication-title: Am J Manag Care – ident: e_1_2_7_11_2 doi: 10.1097/00005650-199401000-00004 – ident: e_1_2_7_15_2 doi: 10.1023/A:1016370925601 – ident: e_1_2_7_24_2 doi: 10.1016/S0090-4295(00)01113-4 – ident: e_1_2_7_28_2 – ident: e_1_2_7_4_2 – volume: 8 start-page: S616 year: 2002 ident: e_1_2_7_12_2 article-title: Long‐term health‐related quality of life of patients receiving extended release tolterodine for overactive bladder. publication-title: Am J Man Care |
| SSID | ssj0067145 |
| Score | 1.8457037 |
| Snippet | Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically... Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease‐specific and generic quality of life (QoL) in females with clinically... We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically diagnosed... Objectives: We evaluated the effectiveness of antimuscarinic treatment on disease-specific and generic quality of life (QoL) in females with clinically... |
| SourceID | unpaywall proquest pubmed crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 5 |
| SubjectTerms | antimuscarinic agent overactive bladder overactive bladder symptom score quality of life Rand Medical Outcomes Study 36-Item Short Form Health Survey |
| Title | Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey |
| URI | https://api.istex.fr/ark:/67375/WNG-N7L908CG-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1757-5672.2012.00155.x https://www.ncbi.nlm.nih.gov/pubmed/26663241 https://www.proquest.com/docview/1346150040 https://www.proquest.com/docview/1749996013 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1757-5672.2012.00155.x |
| UnpaywallVersion | publishedVersion |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1757-5672 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0067145 issn: 1757-5672 databaseCode: ABDBF dateStart: 20120501 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF5VyQFx4K9AjUo1SKg3B7vx2g63pJAWFFJUN6KcVt71Woqa2FEaQ82JR-DxOPMkzKwdq61yAMQlimTPrr07O_vN7Mxnxl5K5UjOZWjHTqpsT2rXDjmnnAY3xeXkdv2EAvofxv7xxHt_zs-32HhdC1PxQzQBN1oZxl7TAl8kaWXnX13Px-GBzf2AaqoorEcQoIOYsu1zxOYt1p6MP_Y_m6pIc6Phk2qEbqX2bGrqxn7VpqG_2gRG77I7RbaIy6_xbHYT55qNanif5etXrPJTLjrFSnbUt1vsj_9vDB6wezWmhX6lhA_Zls4ese1-hv78vIR9MFmmJny_zX7WRKQzeGfqMyFPIcpn01RnsZpmkGdgmLCnCuIsgaicL7CVX99_RAtt0gehYv0oSXCEYoCoG4Z6jhvdJVBUGU5wdcbGjMNgRoZ1-RpMZgQg2N1wdd0JRETpabo9pZ_6DAtOihWOC7ZOOZcldH18GjrhgKqEC6Ji-UWXj9lk-Pbs8Niuvy5hK6I5s3XPSdC5SlAnVJJIrjyJUFjSx-EJd_o9L-0dKEWVuXFPaicJiN0w1DpwvDTkTvcJa2V5pncYeHEaapX4KiRqIz8JtZRuqoLED3yudddi7lqHxKIiERHXnC-cPkHTJ2j6hJk-cWWxfaNsjUC8vKAkvICLT-MjMQ5GPSc8PBKnFttda6Oo7c-lcLseMf2jhbbYi-YyWg46DooznRd4T2C8XfQBLPa00uKmM4RtxOPvWuygUeu_eHTfKO0fC4jR5CzCf8_-pbdd1lotC_0cseFK7rF2f_BmMNyrF_5vKgRdKg |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5VzQFx4FUeRgUNEurNwW68tsMtVKQFhRTVjSinlfdhKWpiR2kMNSd-Aj-PM7-EmbVjtVUOgLhEkezZtXdnZ7-ZnfnM2EupPMm5jN3Uy5QbSOO7MeeU0-BnuJz8XqgpoP9hHB5Ngvdn_GyLjde1MDU_RBtwo5Vh7TUt8IXOajv_6mo-Do9cHkZUU0VhPYIAXcSUnZAjNt9mncn44-CzrYq0N1o-qVboRmrPpqau7VcdGvrLTWD0NrtV5ou0-prOZtdxrt2ohndZsX7FOj_lvFuuZFd9u8H--P_G4B6702BaGNRKeJ9tmfwB2xnk6M_PK9gDm2Vqw_c77GdDRDqDd7Y-E4oMkmI2zUyeqmkORQ6WCXuqIM01JNV8ga38-v4jWRibPgg160dFgiMUA0TdMDRz3OgugKLKcIyrM7VmHN7MyLAuX4PNjAAEuxuurjuBhCg9bbcn9NOcYcFxucJxwdYp57KCXohPQyccUJdwQVIuv5jqIZsM354eHLnN1yVcRTRnrul7Gp0rjTqhtJZcBRKhsKSPwxPuDPtB1t9Xiipz0740no6I3TA2JvKCLOZe7xHbzovcPGEQpFlslA5VTNRGoY6NlH6mIh1GITem5zB_rUNiUZOIiCvOF06foOkTNH3CTp-4dNieVbZWIF2eUxJexMWn8aEYR6O-Fx8cihOH7a61UTT250L4vYCY_tFCO-xFexktBx0HpbkpSrwnst4u-gAOe1xrcdsZwjbi8fcdtt-q9V88emiV9o8FxGhymuC_p__S2y7bXi1L8wyx4Uo-bxb8b0kWW7g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Impact+of+Solifenacin+on+Generic+and+Symptom%E2%80%90Specific+Quality+of+Life+for+Females+with+Overactive+Bladder%3A+Using+the+Overactive+Bladder+Symptom+Score+and+Rand+Medical+Outcomes+Study+36%E2%80%90Item+Health+Survey&rft.jtitle=Lower+urinary+tract+symptoms&rft.au=YANO%2C+Masashi&rft.au=SUZUKI%2C+Hiroyoshi&rft.au=KAMIYA%2C+Naoto&rft.au=KATO%2C+Tomonori&rft.date=2013-01-01&rft.issn=1757-5664&rft.eissn=1757-5672&rft.volume=5&rft.issue=1&rft.spage=5&rft.epage=10&rft_id=info:doi/10.1111%2Fj.1757-5672.2012.00155.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1757_5672_2012_00155_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-5664&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-5664&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-5664&client=summon |